CDK2AP2 Antibody

What is CDK2AP2 and what cellular functions should researchers consider when designing experiments?

CDK2AP2 (Cyclin-dependent Kinase 2-associated Protein 2) functions as a regulator of self-renewal in mouse embryonic stem cells (mESCs) under permissive conditions and is critical for cell survival during differentiation into terminally differentiated cell types. Experiments designed to study CDK2AP2 should account for its biphasic expression pattern during differentiation, suggesting distinct regulatory roles in early versus late stem cell differentiation processes. When designing antibody-based experiments, researchers should consider that CDK2AP2 has been shown to interact with MAPK and is a target for phosphorylation by MAPK and Cyclin B/Cdc2 during meiosis in mouse oocytes .

How should researchers interpret CDK2AP2 expression changes during stem cell differentiation?

When analyzing CDK2AP2 expression during differentiation, researchers should note that Cdk2ap2 shows a characteristic biphasic expression pattern. In wild-type mESCs, Cdk2ap2 expression significantly downregulates at day 2 of differentiation when mESCs exit self-renewal and commit to various germ lineages. Interestingly, expression then reappears at days 5 and 10 in embryoid body (EB) formation assays . This pattern suggests distinct roles in both maintaining pluripotency and supporting cell survival during terminal differentiation. Methodologically, researchers should collect samples at multiple timepoints during differentiation protocols (days 0, 2, 5, and 10 are recommended) to accurately capture this biphasic pattern.

What applications are CDK2AP2 antibodies validated for in research settings?

CDK2AP2 antibodies have been validated for multiple applications including Western blotting (WB), enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), and immunofluorescence (IF) in both cell culture (cc) and paraffin-embedded tissue sections (p) . When selecting an antibody for a specific application, researchers should verify the validation data for their particular experimental system, as reactivity can vary across applications even with the same antibody.

How can researchers distinguish between monomeric and dimeric forms of CDK2AP2?

Western blot analyses have demonstrated that CDK2AP2 can exist in both disulfide-reduced (monomeric) and disulfide-bonded (dimeric) forms in cells. For accurate detection of these different forms, researchers should perform SDS-PAGE under both reducing and non-reducing conditions. In contact-inhibited human diploid cells, the disulfide-bonded dimeric form increases with a concomitant decrease in the disulfide-reduced monomeric form .

Methodologically, researchers can use anti-CDK2AP1 polyclonal antibodies which have demonstrated cross-reactivity with CDK2AP2. When analyzing results, researchers should note that the dimeric form appears to be the active form for inhibition of CDK2. For confirmation of dimeric structure, mutational analysis targeting cysteine residue at position 105 can be performed, as this residue is critical for disulfide bond formation .

How do CDK2AP2 and CDK2AP1 functions differ, and how should antibodies be validated to distinguish between them?

Although CDK2AP2 shares structural similarities with CDK2AP1, their functional roles appear to be distinct and sometimes opposing. Loss of CDK2AP1 maintains a pluripotent state, while loss of CDK2AP2 promotes spontaneous differentiation of mESCs . Researchers should rigorously validate antibody specificity by:

• Performing western blots with recombinant proteins of both CDK2AP1 and CDK2AP2

• Including knockout/knockdown controls for both proteins

• Confirming band sizes (CDK2AP1: ~12 kDa; CDK2AP2: ~13 kDa)

• Conducting peptide competition assays to verify binding specificity

This differential validation is crucial as these proteins may interact with similar complexes but exert opposite effects .

What are the optimal experimental designs for studying CDK2AP2's role in stem cell self-renewal?

To study CDK2AP2's role in stem cell self-renewal, researchers should design experiments that:

• Compare wild-type mESCs with CDK2AP2-knockout or knockdown models

• Analyze expression of pluripotency markers (particularly Nanog, which shows reduced expression in Cdk2ap2-deficient cells while Oct4 remains unchanged)

• Examine expression of lineage-specific markers (mesoderm and endoderm markers like Brachyury(T), Afp, and S100a show increased expression in Cdk2ap2-deficient cells)

• Include functional assays such as embryoid body (EB) formation and teratoma formation

For antibody-based detection in these experiments, researchers should use multiple antibodies targeting different epitopes and include appropriate controls to ensure specificity.

What controls are essential when using CDK2AP2 antibodies in immunofluorescence studies?

When conducting immunofluorescence studies with CDK2AP2 antibodies, researchers should include the following controls:

• Negative controls:

  • Secondary antibody-only control to assess background fluorescence

  • Samples from CDK2AP2 knockout/knockdown cells

  • Isotype controls matching the primary antibody species and isotype

• Positive controls:

  • Cell types known to express CDK2AP2 at high levels

  • Overexpression systems with tagged CDK2AP2 constructs

• Specificity controls:

  • Peptide competition assays

  • Multiple antibodies targeting different epitopes of CDK2AP2

For optimal visualization, counterstain nuclei with DAPI as demonstrated in embryoid body immunofluorescence protocols .

What methodological approaches should be used to study CDK2AP2's role in apoptosis during differentiation?

To study CDK2AP2's role in apoptosis during differentiation, researchers should:

• Generate embryoid bodies (EBs) from wild-type and CDK2AP2-deficient mESCs using the hang-drop protocol

• Harvest EBs at multiple timepoints (days 0, 2, 5, and 10) for expression analysis

• Induce terminal differentiation using retinoic acid (5 μM) or maintain controls with DMSO

• Assess apoptosis through:

  • Immunostaining with antibodies against Annexin V

  • Counterstaining with DAPI to visualize nuclear morphology

  • Quantifying the percentage of apoptotic cells in multiple fields

Comparative analysis between wild-type and CDK2AP2-deficient cells during forced terminal differentiation will reveal CDK2AP2's specific role in protecting cells from apoptosis during this process.

How should researchers design experiments to investigate CDK2AP2-CDK2 interactions?

To investigate interactions between CDK2AP2 and CDK2, researchers should consider:

• Co-immunoprecipitation (Co-IP):

  • Use antibodies against CDK2AP2 to pull down protein complexes

  • Probe for CDK2 and other potential interactors (cyclins A and E)

  • Include appropriate controls (IgG control, input lysate)

• Proximity ligation assays (PLA):

  • Use antibodies against CDK2AP2 and CDK2 from different species

  • Quantify interaction signals in different cell cycle phases

• Functional assays:

  • Analyze CDK2 kinase activity in the presence/absence of CDK2AP2

  • Investigate the formation of CDK2 complexes with cyclins A and E

  • Assess proteasomal degradation of CDK2 in relation to CDK2AP2 levels

These approaches will help elucidate whether CDK2AP2 inhibits CDK2 kinase activity by sequestering the inactive monomer or directing it to the proteasome degradation pathway.

How should researchers interpret discrepancies between CDK2AP2 mRNA and protein levels?

When researchers encounter discrepancies between CDK2AP2 mRNA and protein levels, they should consider:

• Post-transcriptional regulation:

  • MicroRNA-mediated regulation

  • mRNA stability and half-life

  • Alternative splicing events

• Post-translational modifications:

  • Ubiquitination and proteasomal degradation

  • Phosphorylation by MAPK or Cyclin B/Cdc2, which has been demonstrated

  • Disulfide bond formation affecting protein stability

• Methodological approaches for verification:

  • Use multiple primer sets for RT-qPCR targeting different regions

  • Employ antibodies recognizing different epitopes

  • Analyze protein stability using cycloheximide chase assays

  • Examine subcellular localization, as CDK2AP2 shows differential localization during oocyte maturation

This comprehensive approach helps distinguish between biological phenomena and technical artifacts.

What factors might affect CDK2AP2 antibody detection in different experimental contexts?

Several factors can influence CDK2AP2 antibody detection:

• Protein conformation and post-translational modifications:

  • The transition between monomeric and dimeric forms (mediated by Cys-105)

  • Phosphorylation states during different cell cycle phases

  • Protein-protein interactions masking epitopes

• Experimental conditions:

  • Fixation methods (paraformaldehyde vs. methanol)

  • Antigen retrieval techniques for tissue sections

  • Detergent selection for membrane permeabilization

  • Blocking reagents and duration

• Cell type-specific factors:

  • Differentiation state (CDK2AP2 shows biphasic expression during differentiation)

  • Cell cycle phase (CDK2AP2 may have cell cycle-dependent localization)

  • Cell density (contact inhibition affects the ratio of monomeric to dimeric forms)

Researchers should systematically optimize these conditions for their specific experimental system to ensure reliable detection.

How can researchers confirm the specificity of CDK2AP2 antibodies in knockout/knockdown validation studies?

To rigorously validate CDK2AP2 antibody specificity using knockout or knockdown approaches:

• Generate appropriate control models:

  • Use gene-trap or CRISPR-Cas9 technologies to create complete knockouts

  • Employ siRNA or shRNA for transient or stable knockdowns

  • Create rescue models by reintroducing CDK2AP2 expression

• Implement comprehensive validation methods:

  • Perform genotyping by PCR to confirm genetic modifications

  • Conduct northern blot analysis to verify absence of transcript

  • Use RT-qPCR with primers targeting multiple regions

  • Compare wild-type and knockout samples side-by-side in western blots

  • Quantify signal reduction in immunofluorescence studies

• Address potential compensatory mechanisms:

  • Examine expression of related family members (especially CDK2AP1)

  • Monitor expression of interacting partners (CDK2, cyclins)

  • Consider acute vs. chronic depletion effects

This multilayered approach ensures that observed phenotypes are specifically attributable to CDK2AP2 loss rather than off-target effects or antibody cross-reactivity.

What are the recommended methods for studying CDK2AP2's role in cell cycle regulation?

To investigate CDK2AP2's role in cell cycle regulation, researchers should:

• Cell cycle synchronization and analysis:

  • Synchronize cells using methods appropriate for the cell type

  • Perform flow cytometry with propidium iodide staining to assess cell cycle profiles

  • Compare G1, S, and G2/M phase distributions between wild-type and CDK2AP2-deficient cells

  • Monitor CDK2AP2 expression and localization throughout the cell cycle

• CDK2 activity assays:

  • Conduct in vitro kinase assays with immunoprecipitated CDK2

  • Assess phosphorylation of CDK2 substrates

  • Monitor cyclin A and E interactions with CDK2 in the presence/absence of CDK2AP2

• Cell proliferation and growth analyses:

  • Measure growth curves and doubling times

  • Perform BrdU incorporation assays to quantify DNA synthesis

  • Analyze expression of cell cycle regulators (p21, p27, cyclins)

These approaches will help elucidate whether CDK2AP2 influences cell cycle progression primarily through CDK2 inhibition or through alternative mechanisms.

How can researchers effectively study the dynamic interplay between CDK2AP1 and CDK2AP2?

To study the interplay between CDK2AP1 and CDK2AP2, researchers should:

• Generate single and double knockout/knockdown models:

  • Create CDK2AP1-KO, CDK2AP2-KO, and double-KO cell lines

  • Develop inducible expression systems for controlled expression

• Investigate physical interactions:

  • Perform co-immunoprecipitation studies to confirm direct interaction

  • Use proximity ligation assays to visualize interactions in situ

  • Conduct sequential immunoprecipitation to identify shared protein complexes

• Analyze functional consequences:

  • Compare phenotypes of single vs. double knockouts

  • Assess stem cell self-renewal and differentiation capacity

  • Monitor cell cycle profiles and apoptosis rates

  • Examine expression of pluripotency markers and lineage-specific genes

This multifaceted approach will help clarify whether CDK2AP1 and CDK2AP2 function antagonistically, synergistically, or independently in different cellular contexts.